Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T13:46:34.595Z.
Calculation as of: 2026-10-06T13:46:34.595Z.
Quote observation: 2026-10-06T13:45:11.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 16b0ce149acf027305ec47ed69e441f7c4eae43bc3095c7aeda967d53938ba16
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$6.04M
PS Ratio
417.81
TTM Avg
323.54
3Y Avg
12621.52
5Y Avg
612402.72
Market Cap
$5.95M
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.47M
PS Ratio
1.30
TTM Avg
1.37
3Y Avg
1.98
5Y Avg
32.27
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Enlivex Therapeutics Ltd. (ENLV) | $6.07M | N/A | N/A | N/A | N/A |
| Femasys Inc. (FEMY)vs › | $6.22M | 2.71 | 7.98 | 15.65 | 17.17 |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $6.04M | 417.81 | 323.54 | 12621.52 | 612402.72 |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $5.95M | N/A | N/A | N/A | N/A |
| Lucyd, Inc (LUCY)vs › | $5.81M | 1.70 | 2.25 | 4.05 | 7.26 |
| Biomerica, Inc. (BMRA)vs › | $6.42M | 1.44 | 1.51 | 10.02 | 17.31 |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.47M | 5.56 | 4.72 | 4.72 | 4.72 |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.59M | N/A | N/A | N/A | N/A |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.47M | 1.30 | 1.37 | 1.98 | 32.27 |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.49M | N/A | 8.07 | 5.46 | 11.12 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-14 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-25 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-31 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-09-25 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
